KLK6

Aliases
  • Bssp
  • HK-6
  • KLK-6
  • KLK6
  • Kallikrein-6
  • Klk7
  • Neurosin
  • PRSS18
  • PRSS9
  • Protease M
  • SP59
  • Serine protease 18
  • Serine protease 9
  • Zyme
  • kallikrein-related peptidase 6
Description
Serine protease M expressed on epithelial cell surface and released in ECM. Tumor cells treated with a neutralizing KLK6 antibody migrate less than control cells, suggesting a role in invasion and metastasis. Overexpressed in primary breast tumors but not expressed in metastatic tumors.
OncoMX

Search for this biomarker in OncoMX  

Attributes
QA State
Accepted
Type
Protein
HGNC Name
KLK6
Certifications
  • None
QA State for Breast

 Non-Public Biomarker

Organ-specific information for this biomarker is currently being annotated or is "under review". Logging in may give you privileges to view additional information. Contact the Informatics Center if you believe you should have access.

Certifications
  • None
QA State for Ovary
Accepted
Organ-Specific Notes

Amplification of a chromosome 19q region with the entire kallikrein family associated with ovarian cancer.

Performance Comment

Of the 28 ovarian cancer biomarkers tested in prediagnostic specimens, from the PLCO, CA125 remains the single best biomarker for ovarian cancer and has its strongest signal within six months of diagnosis. KLK6 alone was not a strong predictor.

Supporting Study Data
Intergrated Systems Biology Approach for Ovarian Cancer Biomarker Discovery
Study phase on the ovary: 1

The overall objective is to validate serum protein markers for early diagnosis of ovarian cancer with the ultimate goal being to develop a multiparametric panel consisting of 2-4 novel markers with 10 known markers for phase 3 analysis. In phase 1, we will screen for markers able to pass a threshold of 98% specificity and 30% sensitivity in a cohort of 300 women. Markers that pass phase 1 validation will be investigated in a phase 2 PRoBE cohort with a 98% specificity and 70% sensitivity cut-off. Finally, markers that pass phase 2 validation will be evaluated in EDRN CVC laboratory specimens with a cut-off of > 98% specificity and 90% sensitivity.

View Protocol
Decision rule: No decision rule specified.
PLCO Ovarian Phase III Validation Study
Study phase on the ovary: 3

Our preliminary data indicate that the performance of CA 125 as a screening test for ovarian cancer can be improved upon by additional biomarkers. With completion of one additional validation step, we will be ready to test the performance of a consensus marker panel in a phase III validation study. Given the original aims of the PLCO trial, we believe that the PLCO represents an ideal longitudinal cohort offering specimens for phase III validation of ovarian cancer biomarkers.

View Protocol
Decision rule: PMID:21372037
SPORE/EDRN/PRE-PLCO Ovarian Phase II Validation Study
Study phase on the ovary: 3

Create a new set of phase II specimens (160 cases with pre-operative bloods representing major histologic types and including 80 early-staged and 80 late-staged cases, 160 controls with benign disease, 480 general population controls, and a small set of serial Samples collected either at least 3 months apart, but not more than 6 months apart OR between 10 months apart and no more than 14 months apart in 40 healthy controls) will be used to evaluate markers identified in preliminary work. The top 5-10 markers, plus an expanded panel of Luminex markers, will comprise a “working consensus panel” for subsequent analysis in PLCO specimens.

View Protocol
Decision rule: PMID:21372037
Ovary-Specific Protocols
  • No organ-level protocols specified for ovary.
Ovary-Specific Publications
  • No organ-level publications were listed for ovary.
Ovary-Specific Resources
  • No organ-level resources were given for ovary.